Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis1Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc.1
Year: 1999
Type: article
Source: Journal of Neuroimmunology
Authors: Richard A. Rudick, Diane L. Cookfair, Nancy A. Simonian, Richard M. Ransohoff, John R. Richert, Lawrence D. Jacobs, Robert M. Herndon, Andres M. Salazar, Jill S. Fischer, Carl V. Granger, Donald E. Goodkin, Jack H. Simon, David M. Bartoszak, Dennis N. Bourdette, Jonathan Braiman, Carol M. Brownscheidle, Michael E. Coats, Stanley L. Cohan, David S. Dougherty, Revere P. Kinkel, Michele K. Mass, Frederick E. Munchsauer, Kathy O'Reilly, Roger L. Priore, Patrick M. Pullicino, Barbara J. Scherokman, Karl Wende, Bianca Weinstock-Guttman, Ruth H. Whitham
Institutions: Cleveland Clinic, University at Buffalo, State University of New York, Biogen (United States), Georgetown University Medical Center, Legacy Good Samaritan Medical Center, Walter Reed National Military Medical Center, University of California, San Francisco, University of Colorado Denver, Oregon Health & Science University, Kaiser Permanente
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: relapsing multiple sclerosis, interferon beta-1a, Avonex, cerebrospinal fluid biomarkers, oligoclonal bands, IgG index, kappa free light chains, CSF white blood cell count, gadolinium-enhancing lesions, T2 lesion volume, disease activity prediction, treatment response, disability progression, relapse rate, MRI lesion volume
Open Access status: closed
OpenAlex ID: W1244620587
